Suppr超能文献

2017 - 2023年佐治亚州多次接受检测人群中丙型肝炎发病率的时间趋势:一项全国性回顾性队列研究

Temporal trends in hepatitis C incidence among people tested more than once in Georgia, 2017-23: a nationwide, retrospective cohort.

作者信息

Baliashvili Davit, Shadaker Shaun, Furukawa Nathan, Getia Vladimer, Tsereteli Maia, Symum Hasan, Armstrong Paige A, Tohme Rania A, Handanagic Senad

机构信息

The Task Force for Global Health, Tbilisi, Georgia.

Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, GA, USA.

出版信息

Lancet Gastroenterol Hepatol. 2025 Sep;10(9):831-841. doi: 10.1016/S2468-1253(25)00124-4. Epub 2025 Jul 10.

Abstract

BACKGROUND

Achieving low incidence is one of WHO's key targets for the elimination of hepatitis C virus (HCV) infection. As progress in Georgia's hepatitis C elimination programme moves the country closer to reaching this target, tracking new cases of hepatitis C has become a priority. We aimed to estimate temporal trends in hepatitis C incidence among people who were tested more than once for hepatitis C in Georgia.

METHODS

We conducted a retrospective cohort study in adults (aged ≥18 years) tested at least twice for antibodies against HCV (anti-HCV), with the first test being non-reactive, in Georgia from Jan 1, 2017, to Dec 31, 2023. Data were extracted from Georgian national hepatitis C screening and treatment databases on Jan 8, 2024. We calculated the incidence of anti-HCV seroconversion and current chronic HCV infections per 100 000 person-years and 95% CIs overall for 2017-23 and by year for 2017-22. For people who seroconverted but did not undergo testing to confirm current infection, we used multiple imputations to impute the status of current chronic HCV infection. To estimate the magnitude of change, we calculated incidence rate ratios (IRRs) with 95% CIs.

FINDINGS

Among 1 264 181 adults with repeat anti-HCV testing during the study period, 519 936 (41·1%) were men and 744 245 (58·9%) were women. In total, 18 846 (1·5%) seroconverted to anti-HCV-reactive after a median follow-up time of 1025 days (IQR 503-1553). The overall incidence rate of anti-HCV seroconversion was 514 cases per 100 000 person-years (95% CI 506-521). The overall estimated incidence rate of current chronic HCV infection was 293 cases per 100 000 person-years (288-299). The annual incidence rate of anti-HCV seroconversion was 3·7 times lower in 2022 than in 2017, declining from 1399 cases per 100 000 person-years (1346-1454) to 377 cases per 100 000 person-years (361-394; IRR 0·27 [95% CI 0·25-0·29]). The annual incidence rate of chronic HCV infection was 4·6 times lower in 2022 than in 2017, declining from 935 cases per 100 000 person-years (892-981) to 205 cases per 100 000 person-years (193-217; IRR 0·22 [95% CI 0·20-0·24]).

INTERPRETATION

We found a high but decreasing incidence rate of hepatitis C in Georgia among people tested more than once. The country should scale up preventive interventions to reduce incidence further and reach elimination targets.

FUNDING

None.

TRANSLATION

For the Georgian translation of the abstract see Supplementary Materials section.

摘要

背景

实现低发病率是世界卫生组织消除丙型肝炎病毒(HCV)感染的关键目标之一。随着格鲁吉亚丙型肝炎消除计划取得进展,该国离实现这一目标越来越近,追踪丙型肝炎新病例已成为当务之急。我们旨在估算格鲁吉亚多次接受丙型肝炎检测人群中丙型肝炎发病率的时间趋势。

方法

我们在2017年1月1日至2023年12月31日期间对格鲁吉亚年龄≥18岁且至少接受过两次抗HCV抗体检测(首次检测为阴性)的成年人进行了一项回顾性队列研究。数据于2024年1月8日从格鲁吉亚国家丙型肝炎筛查和治疗数据库中提取。我们计算了2017 - 2023年期间每10万人年抗HCV血清学转换和当前慢性HCV感染的发病率及95%置信区间,并按年份计算了2017 - 2022年的发病率。对于血清学转换但未接受检测以确认当前感染状况的人群,我们采用多重填补法估算当前慢性HCV感染状况。为估算变化幅度,我们计算了发病率比(IRR)及95%置信区间。

结果

在研究期间接受重复抗HCV检测的1264181名成年人中,519936名(41.1%)为男性,744245名(58.9%)为女性。共有18846名(1.5%)在中位随访时间1025天(四分位间距503 - 1553天)后血清学转换为抗HCV阳性。抗HCV血清学转换的总体发病率为每10万人年514例(95%置信区间506 - 521)。当前慢性HCV感染的总体估计发病率为每10万人年293例(288 - 299)。2022年抗HCV血清学转换的年发病率比2017年低3.7倍,从每10万人年1399例(1346 - 1454)降至每10万人年377例(361 - 394;发病率比0.27 [95%置信区间0.25 - 0.29])。慢性HCV感染的年发病率2022年比2017年低4.6倍,从每10万人年935例(892 - 981)降至每10万人年205例(193 - 217;发病率比0.22 [95%置信区间0.20 - 0.24])。

解读

我们发现格鲁吉亚多次接受检测人群中丙型肝炎发病率虽高但呈下降趋势。该国应扩大预防干预措施,以进一步降低发病率并实现消除目标。

资金来源

无。

摘要的格鲁吉亚语翻译见补充材料部分。

相似文献

1
Temporal trends in hepatitis C incidence among people tested more than once in Georgia, 2017-23: a nationwide, retrospective cohort.
Lancet Gastroenterol Hepatol. 2025 Sep;10(9):831-841. doi: 10.1016/S2468-1253(25)00124-4. Epub 2025 Jul 10.
3
Pharmacological interventions for acute hepatitis C infection: an attempted network meta-analysis.
Cochrane Database Syst Rev. 2017 Mar 13;3(3):CD011644. doi: 10.1002/14651858.CD011644.pub2.
4
Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs.
Cochrane Database Syst Rev. 2017 Sep 18;9(9):CD012021. doi: 10.1002/14651858.CD012021.pub2.
6
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
7
Isolation as a strategy for controlling the transmission of hepatitis C virus (HCV) infection in haemodialysis units.
Cochrane Database Syst Rev. 2016 Aug 11;2016(8):CD006420. doi: 10.1002/14651858.CD006420.pub2.
8
Progress Toward Hepatitis C Virus Elimination among People Living with HIV-Hepatitis C Virus Coinfection in Canada.
Can Liver J. 2025 Feb 25;8(1):49-62. doi: 10.3138/canlivj-2024-0042. eCollection 2025 Feb.
9
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Cochrane Database Syst Rev. 2020 Jan 9;1(1):CD011535. doi: 10.1002/14651858.CD011535.pub3.
10
NIH Consensus Statement on Management of Hepatitis C: 2002.
NIH Consens State Sci Statements. 2002;19(3):1-46.

本文引用的文献

1
Risk factors for HCV infection in Georgia: A case-control study.
J Infect Dev Ctries. 2025 May 31;19(5):792-796. doi: 10.3855/jidc.20658.
2
A 2024 global report on national policies, programmes, and progress towards hepatitis C elimination: findings from 33 hepatitis elimination profiles.
Lancet Gastroenterol Hepatol. 2025 Jul;10(7):685-700. doi: 10.1016/S2468-1253(25)00068-8. Epub 2025 May 20.
3
Trends in new hepatitis C virus infections among repeat blood donors - Georgia, 2017-2023.
Transfus Clin Biol. 2025 Feb;32(1):39-43. doi: 10.1016/j.tracli.2024.11.004. Epub 2024 Nov 14.
4
Progress Toward the Elimination of Hepatitis B and Hepatitis C in the Country of Georgia, April 2015-April 2024.
MMWR Morb Mortal Wkly Rep. 2024 Aug 1;73(30):660-666. doi: 10.15585/mmwr.mm7330a1.
6
Nationwide Hepatitis C Serosurvey and Progress Towards Hepatitis C Virus Elimination in the Country of Georgia, 2021.
J Infect Dis. 2023 Sep 15;228(6):684-693. doi: 10.1093/infdis/jiad064. Epub 2023 Mar 18.
7
The Incidence and Care Cascade of the Hepatitis C Virus in Korea.
Gut Liver. 2023 Nov 15;17(6):926-932. doi: 10.5009/gnl220322. Epub 2023 Mar 2.
8
Global reporting of progress towards elimination of hepatitis B and hepatitis C.
Lancet Gastroenterol Hepatol. 2023 Apr;8(4):332-342. doi: 10.1016/S2468-1253(22)00386-7. Epub 2023 Feb 8.
9
Prevalence of and risk factors for HCV among incarcerated people at Great Tehran Prison: a cross-sectional study.
Int J Prison Health. 2023 Nov 28;19(4):536-544. doi: 10.1108/IJPH-09-2022-0059. Epub 2023 Feb 13.
10

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验